European Urology - A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
Friday, 17 November 2006
Abstract - Objectives: This study compared the complications and the cancer control of elective nephron-sparing surgery (NSS) and radical nephrectomy (RN) in patients with a small (≤5cm), solitary, low-stage N0 M0 tumour suspicious for renal cell carcinoma (RCC) and a normal contralateral kidney.
read more
|
Short-Course Radiotherapy (RT) for Metastatic Spinal Cord Compression (MSCC) Due to Renal Cell Carcinoma: Results of a Retrospective Multi-Center Study
Saturday, 06 May 2006
Objective: For MSCC treatment, a short treatment time is desirable, especially if survival prognosis is poor. Survival depends on the primary tumor, extent of disease, performance status, ambulatory status, and the number of involved vertebrae.
read more
|
2004 WHO Classification of the Renal Tumors of the Adults
Saturday, 06 May 2006
Background: The recently introduced 2004 World Health Organisation (WHO) classification of the adult renal epithelial neoplasms is meant to replace the previous 1998 WHO classification.
read more
|
European Urology - Prosthetic Nephrovesical Bypass
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 879-883 Article Outline: Patients with advanced malignant masses in the retroperitoneum often present with renal failure due to ureteral obstruction.
read more
|
European Urology - Expanding the Indications for Elective Partial Nephrectomy: Is this Advisable?
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 952-954 (June 2006) Just when the issue of elective partial nephrectomy appeared to be settled, it is now controversial again, with some centres proposing an expansion of indications to include larger tumour size (4.0–7.0cm).
read more
|
Retroperitoneoscopic Versus Open Surgical Radical Nephrectomy for Large Renal Cell Carcinoma in Clinical Stage cT2 or cT3a: Quality of Life, Pain and Reconvalescence
Wednesday, 01 February 2006
Objectives: To determine whether retroperitoneoscopic radical nephrectomy for large renal cell carcinoma in stage cT2 or cT3a is a feasible, safe and effective therapy option and if it shows any advantage regarding quality of life in comparison to open procedure.
read more
|
Elective Nephron Sparing Surgery Should Become Standard Treatment for Small Unilateral Renal Cell Carcinoma: Long-term Survival Data of 216 Patients
Wednesday, 01 February 2006
Objectives: Our experiences with elective nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) in a consecutive series of 216 patients are presented. Clinicopathological features and long-term oncological outcome is compared to patients treated with radical nephrectomy (RN).
read more
|
European Urology - Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma: At a Low Ebb?
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 11-13 (July 2006)
1. Dendritic cell vaccination and adoptive cellular therapy in the management of metastatic renal cell carcinoma: a smart concept for an old story.
read more
|
European Urology - Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 92-97 (July 2006) 1. Introduction: Renal cell carcinoma (RCC) is the third most common genitourinary tumor, accounting for 3% of all cancers in the United States [1]. Recently, 10-yr survival rate of all RCC has reached >65% due to the improvements in diagnostic imaging techniques and better treatment [2], [3].
read more
|
European Urology - Surgical Care, Morbidity, Mortality and Follow-up after Nephrectomy for Renal Cancer with Extension of Tumor Thrombus into the Inferior Vena Cava: Retrospective Study Since 1990s
Wednesday, 19 July 2006
Volume 50, Issue 2, Pages 302-310 (August 2006)1. Introduction: The management of localized and metastatic renal cancer has changed in the last 20 years, predicated on major advancements in renal imaging, surgical techniques and development of effective adjuvant therapies like immunotherapies [1].
read more
|
Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
Monday, 03 April 2006
Objective: To understand the mode of action of the currently most investigated new drugs in renal cell carcinoma (RCC) and ultimately to analyze what should be the role of the urologist in this new therapeutic era.
read more
|
Reassessing the Current TNM Lymph Node Staging for Renal Cell Carcinoma
Wednesday, 01 February 2006
Objectives: The most commonly used staging system for renal cell carcinoma (RCC) is the tumor-node-metastasis (TNM) system. In the most recent TNM edition, lymph node (LN) involvement is defined as pN0, pN1, or pN2, depending on the number of metastatic LNs (none, 1, or >1). This study evaluated the prognostic value of this classification and tried to improve its clinical impact by considering an additional parameter, that is, LN density (ratio between number of positive LNs and total number of LNs retrieved).
read more
|
Nephron-Sparing Surgery for Renal Cell Carcinoma: Detailed Analysis of Complications Over a 15-Year
Wednesday, 01 March 2006
Purpose: To assess the incidence of complications of conservative renal surgery for renal cell carcinoma in both elective and imperative indications, and its evolution over a 15 year period.
read more
|
European Urology - Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas
Friday, 01 September 2006
Volume 50, Issue 3, Pages 530-534 (September 2006)
Abstract -
Background:
Growth of solid tumors requires angiogenesis. Evidence indicates that mast cells (MCs) play an important role in tumor angiogenesis.
read more
|
European Urology - Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1272-1277 (December 2006) Abstract - Objectives: Angiogenesis is important for tumour progression and metastatic spread. Hypoxia-inducible factor 1α (HIF-1α) is a major factor regulating a number of other angiogenic factors.
read more
|
European Urology - Tumor Size Improves the Accuracy of TNM Predictions in Patients with Renal Cancer
Friday, 01 September 2006
Volume 50, Issue 3, Pages 521-529 (September 2006) Abstract - Objectives: Current staging for renal cancer (RC) does not directly rely on tumor size. We examined the increment in accuracy related to inclusion of pathologically determined tumor size in prediction of nodal metastases (N+), distant metastases (M+), and cancer-specific survival (CSS).
read more
|
European Urology - Simple Enucleation for the Treatment of PT1a Renal Cell Carcinoma: Our 20-Year Experience
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1263-1271 (December 2006) Abstract - Objectives: To evaluate the safety and efficacy of simple enucleation as a conservative treatment for pT1a RCC, and to report on the incidence of major complications, local recurrence, and progression-free and disease-specific survival rates.
read more
|
European Urology - Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model
Friday, 22 September 2006
Volume 50, Issue 4, Pages 795-800 (October 2006) Abstract -
Objectives:
Stereotactic body radiation therapy (SBRT) is a new therapeutic paradigm that uses a very large dose per fraction treatments (ablative hypofractionation). We investigated the use of ablative hypofractionation in treating human renal cell carcinoma using a nude mouse model.
read more
|
European Urology - Prognostic Role of the Histologic Subtypes of Renal Cell Carcinoma after Slide Revision
Friday, 22 September 2006
Volume 50, Issue 4, Pages 786-794 (October 2006) Abstract -
Objectives:
To evaluate concordance, using the kappa statistic, between tumour histotypes assigned at initial diagnosis and those after slide revision, and to assess the independent predictive value of reviewed tumour histotype.
read more
|
European Urology - Therapeutic Dendritic Cell Vaccination of Patients with Renal Cell Carcinoma
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 34-43 (July 2006) 1. Introduction: Renal cell carcinoma (RCC) is a relatively rare disease, comprising approximately 2% of all malignancies.
read more
|
Interferon alpha 2b as Medical Selection for Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma: A Consecutive Study
Monday, 02 January 2006
Objective: Up to 25% of the patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nephrectomy and interferon alpha-2b (IFN-α) will progress rapidly at metastatic sites and undergo needless surgery for an asymptomatic primary. We reversed the timing of surgery and immunotherapy and evaluated the role of initial IFN-α as selection for nephrectomy.
read more
|
